#WCLC19 Registrational results for LOXO-292, now Selpercatinib, presented by @alexdrilon. This is a highly selective RET inhibitor with preclinical CNS activity. Enrolled remarkably quickly: 253 RET+ #NSCLC enrolled since May 2017! #OncoAlert #LCSM
#WCLC19 Selpercatinib patient demographics. Incredible waterfall plot! In previously treated ORR 68% and nearly all patients with some reduction. CNS ORR 91%. Even better in 1L: 85%! mPFS 18.4 months. Impressive results for #RET #NSCLC #OncoAlert
#WCLC19 Illustrative examples of the depth of response possible. Safety profile very reassuring. Impressive results from Selpercatinib - now awaiting update from BLU-667. A great time for #RET targeting! #OncoAlert #LCSM #PrecisionMedicine
With these kinds of waterfalls and durable responses - you have to be checking for #RET and the need for #NGS, preferably RNA-seq, is even more pressing for the proper management of advanced #NSCLC #WCLC19
#WCLC19 Discussion by @rdoebele - success where others have failed. Now need to understand acquired resistance. With a new treatment, we have to rework our understanding of #RET TKI resistance. Also need to compare to BLU-667. #OncoAlert
#WCLC19 Cross trial comparison between Selpercatinib and BLU-667 (now Praseltinib). Both highly active. Some differences but too early to compare.
#WCLC19 Key point by @rdoebele in considering the responses with these highly selective #RET inhibitors: Is a Phase III trial really needed? Personally, would you even have equipoise if the drugs were available?#OncoAlert #LCSM #PrecisionMedicine
Do we need a large Phase III trial comparing selective RET inhibitors like Selpercatinib to chemotherapy or chemo/immunotherapy? #WCLC19 #OncoAlert
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.